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Abstract
We describe the ability of an engineered glycosyltransferase (OleD Loki) to catalyze the N-
glycosylation of tertiary-amine-containing drugs and trichostatin hydroxamate glycosyl ester 
formation. As such, this study highlights the first bacterial model catalyst for tertiary-amine N-
glycosylation and further expands the substrate scope and synthetic potential of engineered OleDs. 
In addition, this work could open the door to the discovery of similar capabilities among other 
permissive bacterial glycosyltransferases.
Graphical Abstract
Bacterial model catalyst: The use of a high-throughput colorimetric screen to identify new 
substrates revealed the engineered macrolide glycosyltransferase OleD Loki as the first reported 
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bacterial glycosyltransferase capable of tertiary-amine N-glycosylation. This study also revealed 
the same enzyme to catalyze trichostatin hydroxamate glycosyl ester formation.
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Glycosyltransferases (GTs), among which sugar nucleotide-dependent GTs (also referred to 
as Leloir GTs) are the most prevalent, mediate the regio- and stereospecific 
glycoconjugation of diverse sugars to a broad range of acceptors.[1] Although Leloir GT-
catalyzed formation of O-glycosides is the most common, corresponding microbial GTs 
involved in the biosynthesis of C-,[2] S-,[3] and N-glycosides have also been characterized. 
Biochemically characterized representative native N-GTs include the indole N-modifying 
GTs involved in the biosynthesis of indolocarbazoles (AtmG, RebG, NokL, and StaG),[4] the 
streptothricin guanidino N-modifying GT StnG[5] and bacterial protein/ansamitocin 
asparagine side chain amide-modifying N-GTs (HMWC, NGT, and Asm25).[6] The gene 
encoding the putative mannopeptimycin guanidino N-modifying GT has also been 
reported,[7] and recent studies of the macrolide-inactivating O-GT OleD,[8] and 
corresponding engineered/evolved variants, revealed OleD-catalyzed N-glucosylation of 
model aromatic/benzyl primary and secondary amines and alkoxyamines.[9] Although 
examples of tertiary-amine N-glucuronidation of drugs have been reported as part of phase II 
metabolism,[10] to the best of our knowledge, bacterial/fungal comparators are 
unprecedented. Within this context, herein we describe the discovery that engineered OleDs 
can catalyze the N-glycosylation of a set of model tertiary-amine-containing drugs and the 
formation of hydroxamate glycosyl esters. As such, the work put forth further expands the 
substrate scope and synthetic potential of enhanced OleDs and presents a complement to 
conventional synthetic strategies to access quaternary amino-N-glycosides.[11]
Inspired by the general reversibility of GT-catalyzed reactions,[12] we recently used simple 
aromatic glycosides as efficient donors in GT-catalyzed sugar nucleotide synthesis and 
coupled transglycosylation reactions.[9a, 13] Importantly, the use of 2-chloro-4-nitrophenyl 
(ClNP) glycoside donors in this context also offered a convenient colorimetric screen to 
enable the directed evolution of enhanced GTs with broad substrate permissivity and the 
identification of new GT substrates (Figure 1 A).[9a] Using ClNP-β-D-Glc and the OleD 
variant Loki,[9a] this colorimetric assay was applied to a panel of 28 representative aliphatic 
tertiary-amine-containing drugs (Figure S1 the Supporting Information). Assays [1 mM 
putative acceptor, 2 mM ClNP-β-D-Glc, 0.1 mM UDP, 25 mM Tris (pH 8.0), 5 mM MgCl2, 
0.25 µM OleD Loki, 20 µL total volume, 30°C, 8 h] were conducted in triplicate in 384-well 
plates, and progress was monitored through the change in absorbance at 410 nm (ΔA410). 
Each plate also contained positive (4-methylumbeliferone; 4-MeUmb)[14] and negative (no 
acceptor, DMSO) comparator controls. Nine putative primary hits were identified (ΔA410>2 
standard deviations above the negative control) in this first-phase screen. Reaction mixtures 
identified as hits were subsequently subjected to HPLC, desalted,[15] and analyzed by LC-
MS to confirm or refute glycoside formation. This streamlined strategy revealed eight 
tertiary amines as validated OleD substrates (Figure 1 B), none of which contained 
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prototypical GT acceptor O-, S-, or N-nucleophiles. To elucidate the nature of the glycosides 
formed, substrates 1 and 2 were selected for subsequent scale-up and full structure 
elucidation based on relative turnover in analytical scale reactions (Figure 1C).
Scaled-up reactions for the chemoenzymatic synthesis of the 1 and 2 glucosides were 
conducted in a total volume of 30 mL [1 mM aglycon, 2 mM ClNP-β-D-Glc, 0.1 mM UDP, 25 
mM Tris (pH 8.0), 5 mM MgCl2, 0.25 µM OleD Loki, 30°C, 24 h]. Reaction progress was 
monitored in real time through ΔA410, and upon completion, reactants and products were 
captured by XAD-16 solid-phase extraction, and the resulting glucosides were subsequently 
purified by HPLC and size-exclusion chromatography. The molecular formulae of the 
corresponding products were established as C23H30ClN2O5S and C25H34ClN2O5 by HR-
ESIMS; these are consistent with the glucosylation of 1 and 2, respectively. Interestingly, 1H 
and 13C NMR spectra of 1a and 2a also revealed signatures that are consistent with atypical 
glucoside formation. Closer analysis revealed 3′-CH2, 4′-CH3, and 5′-CH3 1H and 13C 
NMR chemical shifts and clear HMBC correlations that were consistent with quaternary 
aminoglucosides 3′-N-β-D-glucosylchlorpromazine (1a) and 3′-N-β-D-
glucosylclomipramine (2a; Scheme 1, Tables S1 and S2). Additional COSY and HMBC 
correlations (Figure S5) were also consistent with this assignment.
The discovery that OleD Loki could catalyze tertiary-amine N-glucosylation prompted a 
reassessment of additional tertiary-amine-bearing substrates previously identified as OleD 
Loki substrates—the naturally occurring HDAC inhibitor trichostatin A (9);[16] the c-Raf 
inhibitor ZM 336372 (10)[17] and the macrolide antibiotic timulcosin (11; Scheme 2)[18]—
through colorimetric screening and LC-MS.[9a] For these selected targets, the strategies 
employed for reaction scale-up, product isolation, and characterization paralleled those 
described for 1a and 2a. The molecular formulae of the purified glycosides were established 
by HR-ESIMS to be C23H32N2O8, C29H33N3O8, and C52H90N2O18; these are consistent 
with the glucosylation of 9, 10, and 11, respectively. Unlike for 1a and 2a, the 1H and 13C 
NMR spectra of the isolated glucosides revealed signatures that were consistent with O-
glucoside formation. Consistent with this, 1D and 2D NMR data revealed 9a to be the 
unique glucopyranosyl hydroxamate trichostatin C and notably highlight the first one-step 
synthesis of this previously reported rare natural product.[19] In a similar fashion, the 1D and 
2D NMR data revealed 10a to be 4-O-β-D-glucosyl-ZM336372 and 11 a to be 2′-O-β-D-
glucosyltilmicosin, the latter is consistent with the native activity of wtOleD as a macrolide-
inactivating glucosyltransferase.[8b]
To the best of our knowledge, this study highlights the first reported example of a microbial 
GT that is capable of catalyzing tertiary-amine N-glycosylation. A comparison of the kinetic 
parameters reveals that the catalytic competencies of tertiary amine 1 (kcat/Km=2.2×10−4 
µM−1 s−1) and hydroxamate 9 (kcat/Km=1.4×10−4 µM−1 s−1) rival that of the parental OleD 
Loki acceptor 4-MeUmb (kcat/Km=2.2×10−4 µM−1 s−1). Although tertiary-amine N-
glucuronidation has been reported in the context of phase II metabolism,[10] fundamental 
biochemical study of the corresponding glucuronsyltransferases has been hampered by 
limited access to suitable in vitro models. Likewise, although sugar conjugation is known to 
influence small-molecule mechanisms, potency, and ADMET,[1a, e, 20] a lack of practical 
synthetic or chemoenzymatic access has limited studies to probe the fundamental properties 
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of quaternary N-glycosides.[10,11] Our discovery offers a convenient new model for GT-
catalyzed tertiary-amine N-glycosylation and a potential complementary synthetic platform 
for efficient one-step synthesis of quaternary N-glycosides. In a similar fashion, the 
discovery that OleD Loki is an efficient catalyst for hydroxamate glycosyl ester synthesis 
further extends the demonstrated synthetic utility of this permissive catalyst. Analysis of the 
established substrates 1–8 highlights a common alkyl N,N-dimethyl acceptor nucleophile 
that extends from a hydrophobic aromatic core reminiscent of the longer unsaturated spacer 
separating the 9 pharmacophore and warhead or the previously reported ability of OleD ASP 
to catalyze asymmetric 4′-O-glycosylation of one “arm” of mitoxantrone.[21] The lack of 
detectable tertiary-amine N-glycosylation with substrates 9–11 may be attributed to substrate 
orientation in the enzyme-bound complex (as suggested by the determined OleD:macrolide 
complex, Figure 2) and/or poor nucleophilicity (as anticipated in the context of the N, N-
dimethyl aniline moiety of 9 and 10).[22] Although these examples suggest that certain 
substrate specificity features might infringe on OleD Loki-catalyzed tertiary-amine reactant 
scope, the underlying discovery also importantly implicates N, N-dimethylamino- and/or 
hydroxamate-functionalized small molecules as a potential acceptors to evaluate in the 
context of other permissive GTs.[23]
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported, in part, by National Institute of Health grants R37 AI52218 (J.S.T.) and U01 GM098248 
(G.N.P.), the National Center for Advancing Translational Sciences (UL1TR001998), the University of Kentucky 
College of Pharmacy and the University of Kentucky Center for Pharmaceutical Research and Innovation.
References
1. a) Elshahawi SI, Shaaban KA, Kharel MK, Thorson JS. Chem. Soc. Rev. 2015; 44:7591–7697. 
[PubMed: 25735878] b) Gloster TM. Curr. Opin. Struct. Biol. 2014; 28:131–141. [PubMed: 
25240227] c) Breton C, Fournel-Gigleux S, Palcic MM. Curr. Opin. Struct. Biol. 2012; 22:540–549. 
[PubMed: 22819665] d) Chang A, Singh S, Phillips GN Jr, Thorson JS. Curr. Opin. Biotechnol. 
2011; 22:800–808. [PubMed: 21592771] e) Gantt RW, Peltier-Pain P, Thorson JS. Nat. Prod. Rep. 
2011; 28:1811–1853. [PubMed: 21901218] f) Palcic MM. Curr. Opin. Chem. Biol. 2011; 15:226–
233. [PubMed: 21334964] g) Roychoudhury R, Pohl NL. Curr. Opin. Chem. Biol. 2010; 14:168–
173. [PubMed: 20129812] h) Lairson LL, Henrissat B, Davies GJ, Withers SG. Annu. Rev. 
Biochem. 2008; 77:521–555. [PubMed: 18518825] i) Bowles D, Lim EK, Poppenberger B, Vaistij 
FE. Annu. Rev. Plant Biol. 2006; 57:567–597. [PubMed: 16669774] 
2. a) Chen D, Chen R, Wang R, Li J, Xie K, Bian C, Sun L, Zhang X, Liu J, Yang L, Ye F, Yu X, Dai J. 
Angew. Chem. Int. Ed. 2015; 54:12678–12682. Angew. Chem. 2015, 127, 12869–12873. b) Foshag 
D, Campbell C, Pawelek PD. Biochim. Biophys. Acta Proteins Proteomics. 2014; 1844:1619–
1630.c) Gutmann A, Krump C, Bungaruang L, Nidetzky B. Chem. Commun. 2014; 50:5465–
5468.d) Li L, Wang P, Tang Y. J. Antibiot. 2014; 67:65–70. [PubMed: 24022606] e) Wang F, Zhou 
M, Singh S, Yennamalli RM, Bingman CA, Thorson JS, Phillips GN Jr. Proteins. 2013; 81:1277–
1282. [PubMed: 23526584] f) Gutmann A, Nidetzky B. Angew. Chem. Int. Ed. 2012; 51:12879–
12883. Angew. Chem. 2012, 124, 13051–13056. g) Härle J, Günther S, Lauinger B, Weber M, 
Kammerer B, Zechel DL, Luzhetskyy A, Bechthold A. Chem. Biol. 2011; 18:520–530. [PubMed: 
21513888] h) Mittler M, Bechthold A, Schulz GE. J. Mol. Biol. 2007; 372:67–76. [PubMed: 
17640665] i) Baig I, Kharel M, Kobylyanskyy A, Zhu L, Rebets Y, Ostash B, Luzhetskyy A, 
Bechthold A, Fedorenko VA, Rohr J. Angew. Chem. Int. Ed. 2006; 45:7842–7846. Angew. Chem. 
Hughes et al. Page 4













2006, 118, 8006–8010. j) Liu T, Kharel MK, Fischer C, McCormick A, Rohr J. ChemBioChem. 
2006; 7:1070–1077. [PubMed: 16795121] k) Fischbach MA, Lin H, Liu DR, Walsh CT. Proc. Natl. 
Acad. Sci. USA. 2005; 102:571–576. [PubMed: 15598734] l) Bililign T, Hyun CG, Williams JS, 
Czisny AM, Thorson JS. Chem. Biol. 2004; 11:959–969. [PubMed: 15271354] 
3. Kopycki J, Wieduwild E, Kohlschmidt J, Brandt W, Stepanova AN, Alonso JM, Pedras MS, Abel S, 
Grubb CD. Biochem. J. 2013; 450:37–46. [PubMed: 23150922] 
4. a) Chiu HT, Lin YC, Lee MN, Chen YL, Wang MS, Lai CC. Mol. Biosyst. 2009; 5:1192–1203. 
[PubMed: 19756309] b) Gao Q, Zhang C, Blanchard S, Thorson JS. Chem. Biol. 2006; 13:733–743. 
[PubMed: 16873021] c) Sánchez C, Méndez C, Salas JA. Nat. Prod. Rep. 2006; 23:1007–1045. 
[PubMed: 17119643] d) Zhang C, Albermann C, Fu X, Peters NR, Chisholm JD, Zhang G, Gilbert 
EJ, Wang PG, Van Vranken DL, Thorson JS. ChemBioChem. 2006; 7:795–804. [PubMed: 
16575939] e) Salas AP, Zhu L, Sánchez C, Braña AF, Rohr J, Méndez C, Salas JA. Mol. Microbiol. 
2005; 58:17–27. [PubMed: 16164546] f) Hyun CG, Bililign T, Liao J, Thorson JS. ChemBioChem. 
2003; 4:114–117. [PubMed: 12512086] g) Sánchez C, Butovich IA, Braña AF, Rohr J, Méndez C, 
Salas JA. Chem. Biol. 2002; 9:519–531. [PubMed: 11983340] h) Ohuchi T, Ikeda-Araki A, 
Watanabe-Sakamoto A, Kojiri K, Nagashima M, Okanishi M, Suda H. J. Antibiot. 2000; 53:393–
403. [PubMed: 10866221] 
5. Guo Z, Li J, Qin H, Wang M, Lv X, Li X, Chen Y. Angew. Chem. Int. Ed. 2015; 54:5175–5178. 
Angew. Chem. 2015, 127, 5264–5267. 
6. a) Gawthorne JA, Tan NY, Bailey U-M, Davis MR, Wong LW, Naidu R, Fox KL, Jennings MP, 
Schulz BL. Biochem. Biophys. Res. Commun. 2014; 445:633–638. [PubMed: 24565833] b) 
Naegeli A, Michaud G, Schubert M, Lin CW, Lizak C, Darbre T, Reymond JL, Aebi M. J. Biol. 
Chem. 2014; 289:24521–24532. [PubMed: 24962585] c) Choi KJ, Grass S, Paek S, St Geme JW 
III, Yeo HJ. PLoS One. 2010; 5:e15888. [PubMed: 21209858] d) Grass S, Lichti CF, Townsend RR, 
Gross J, St Geme JW III. PLoS Pathog. 2010; 6:e1000919. [PubMed: 20523900] e) Zhao P, Bai L, 
Ma J, Zeng Y, Li L, Zhang Y, Lu C, Dai H, Wu Z, Li Y, Wu X, Chen G, Hao X, Shen Y, Deng Z, 
Floss HG. Chem. Biol. 2008; 15:863–874. [PubMed: 18721757] 
7. Magarvey NA, Haltli B, He M, Greenstein M, Hucul JA. Antimicrob. Agents Chemother. 2006; 
50:2167–2177. [PubMed: 16723579] 
8. a) Quirós LM, Aguirrezabalaga I, Olano C, Méndez C, Salas JA. Mol. Microbiol. 1998; 28:1177–
1185. [PubMed: 9680207] b) Hernández C, Olano C, Méndez C, Salas JA. Gene. 1993; 134:139–
140. [PubMed: 8244027] 
9. a) Gantt RW, Peltier-Pain P, Cournoyer WJ, Thorson JS. Nat. Chem. Biol. 2011; 7:685–691. 
[PubMed: 21857660] b) Gantt RW, Goff RD, Williams GJ, Thorson JS. Angew. Chem. Int. Ed. 
2008; 47:8889–8892. Angew. Chem. 2008, 120, 9021–9024. c) Yang M, Proctor MR, Bolam DN, 
Errey JC, Field RA, Gilbert HJ, Davis BG. J. Am. Chem. Soc. 2005; 127:9336–9337. [PubMed: 
15984838] 
10. a) Kim HJ, Jeong ES, Seo KA, Shin KJ, Choi YJ, Lee SJ, Ghim JL, Sohn DR, Shin JG, Kim DH. 
Drug Metab. Dispos. 2013; 41:1529–1537. [PubMed: 23704698] b) Qian MR, Zeng S. Acta 
Pharmacol. Sin. 2006; 27:623–628. [PubMed: 16626519] c) Green MD, King CD, Mojarrabi B, 
Mackenzie PI, Tephly TR. Drug Metab. Dispos. 1998; 26:507–512. [PubMed: 9616184] d) Green 
MD, Tephly TR. Drug Metab. Dispos. 1998; 26:860–867. [PubMed: 9733664] e) Hawes EM. 
Drug Metab. Dispos. 1998; 26:830–837. [PubMed: 9733660] f) Green MD, Tephly TR. Drug 
Metab. Dispos. 1996; 24:356–363. [PubMed: 8820428] g) Green MD, Bishop WP, Tephly TR. 
Drug Metab. Dispos. 1995; 23:299–302. [PubMed: 7628292] h) Lehman JP, Fenselau C, Depaulo 
JR. Drug Metab. Dispos. 1983; 11:221–225. [PubMed: 6135580] i) Lehman JP, Fenselau C. Drug 
Metab. Dispos. 1982; 10:446–449. [PubMed: 6128190] j) Chaudhuri NK, Servando OA, 
Manniello MJ, Luders RC, Chao DK, Bartlett MF. Drug Metab. Dispos. 1976; 4:372–378. 
[PubMed: 8293] k) Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ. Drug Metab. 
Dispos. 1975; 3:189–197. [PubMed: 238818] 
11. a) Iddon L, Bragg RA, Harding JR, Pidathala C, Basca J, Kriby AJ, Stachulski AV. Tetrahedron. 
2009; 65:6396–6402.b) Iddon L, Bragg RA, Harding JR, Stachulski AV. Tetrahedron. 2010; 
66:537–541.
12. a) Zhang C, Bitto E, Goff RD, Singh S, Bingman CA, Griffith BR, Albermann C, Phillips GN Jr, 
Thorson JS. Chem. Biol. 2008; 15:842–853. [PubMed: 18721755] b) Zhang C, Moretti R, Jiang J, 
Thorson JS. ChemBioChem. 2008; 9:2506–2514. [PubMed: 18798210] c) Zhang C, Fu Q, 
Hughes et al. Page 5













Albermann C, Li L, Thorson JS. ChemBioChem. 2007; 8:385–390. [PubMed: 17262863] d) 
Zhang C, Albermann C, Fu X, Thorson JS. Am. Chem. Soc. J. 2006; 128:16420–16421.e) Zhang 
C, Griffith BR, Fu Q, Albermann C, Fu X, Lee IK, Li L, Thorson JS. Science. 2006; 313:1291–
1294. [PubMed: 16946071] f) Minami A, Uchida R, Eguchi T, Kakinuma K. J. Am. Chem. Soc. 
2005; 127:6148–6149. [PubMed: 15853301] 
13. a) Chen Z, Zhang J, Singh S, Peltier-Pain P, Thorson JS, Hinds BJ. ACS Nano. 2014; 8:8104–8112. 
[PubMed: 25025628] b) Singh S, Peltier-Pain P, Tonelli M, Thorson JS. Org. Lett. 2014; 16:3220–
3223. [PubMed: 24911465] c) Zhang J, Singh S, Hughes RR, Zhou M, Sunkara M, Morris AJ, 
Thorson JS. ChemBioChem. 2014; 15:647–652. [PubMed: 24677528] d) Gantt RW, Peltier-Pain P, 
Singh S, Zhou M, Thorson JS. Proc. Natl. Acad. Sci. USA. 2013; 110:7648–7653. [PubMed: 
23610417] e) Peltier-Pain P, Marchillo K, Zhou M, Andes DR, Thorson JS. Org. Lett. 2012; 
14:5086–5089. [PubMed: 22984807] 
14. Williams GJ, Zhang C, Thorson JS. Nat. Chem. Biol. 2007; 3:657–662. [PubMed: 17828251] 
15. Gilar M, Belenky A, Wang BH. J. Chromatogr. A. 2001; 921:3–13. [PubMed: 11461010] 
16. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Clin. Cancer Res. 2001; 
7:971–976. [PubMed: 11309348] 
17. a) Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H. J. Surg. Res. 2006; 133:42–45. [PubMed: 
16603190] b) Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. Mol. Cancer Ther. 2005; 
4:910–917. [PubMed: 15956248] 
18. a) Inamoto T, Kikuchi K, Iijima H, Kawashima Y, Nakai Y, Ogimoto K. J. Vet. Med. Sci. 1994; 
56:917–921. [PubMed: 7865594] b) Zhang N, Tao L, Chang J. Life Sci. J. 2010; 7:107–110.
19. Tsuji N, Kobayashi M. J. Antibiot. 1978; 31:939–944. [PubMed: 711616] 
20. a) Calvaresi EC, Hergenrother PJ. Chem. Sci. 2013; 4:2319–2333. [PubMed: 24077675] b) Jones 
EM, Polt R. Front. Chem. 2015; 3c) Moradi SV, Hussein WM, Varamini P, Simerska P, Toth I. 
Chem. Sci. 2016; 7:2492–2500.
21. Zhou M, Thorson JS. Org. Lett. 2011; 13:2786–2788. [PubMed: 21528870] 
22. a) Ammer J, Baidya M, Kobayashi S, Mayr H. J. Phys. Org. Chem. 2010; 23:1029–1035.b) Ofial 
AR, Mayr H, Phys J. Org. Chem. 2008; 21:584–595.
23. a) Parajuli P, Pandey RP, Trang NT, Oh TJ, Sohng JK. Carbohydr. Res. 2015; 418:13–19. 
[PubMed: 26513760] b) Song C, Gu L, Liu J, Zhao S, Hong X, Schulenburg K, Schwab W. Plant 
Cell Physiol. 2015; 56:2478–2493. [PubMed: 26454881] c) Pandey RP, Parajuli P, Koirala N, Lee 
JH, Park YI, Sohng JK. Mol. Cells. 2014; 37:172–177. [PubMed: 24599002] d) Pandey RP, 
Gurung RB, Koirala N, Tuoi LT, Sohng JK. Carbohydr. Res. 2014; 393:26–31. [PubMed: 
24893262] e) Ono E, Homma Y, Horikawa M, Kunikane S, Imai H, Takahashi S, Kawai Y, 
Ishiguro M, Fukui Y, Nakayama T. Plant Cell. 2010; 22:2856–2871. [PubMed: 20693356] f) 
Blanco G, Patallo EP, Braña AF, Trefzer A, Bechthold A, Rohr J, Méndez C, Salas JA. Cell Chem. 
Biol. 2001; 8:253–263.
Hughes et al. Page 6














A) Schematic of colorimetric high-throughput screen. B) Tertiary-amine-containing 
pharmacophores identified as putative OleD Loki substrates: chlorpromazine (1), 
clomipramine (2), cyclobenzaprine (3), triflupromazine (4), imipramine (5), amitriptyline 
(6), doxepin (7), and diltiazem (8). C) Reaction progress as monitored by ΔA410 in the 
standard 50 mL assay format [see (A) and main text]. Vehicle without acceptor served as the 
negative control, and 4-MeUmb served as the positive control. Assays were conducted in 
triplicate with less than 5% error between replicates.
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Crystal structure of wtOleD bound to erythromycin (PDB ID: 2IYF). Dotted lines highlight 
the proximity of the known acceptor nucleophile (desosamine 2′-OH, which corresponds to 
the mycaminose 2′-OH in 11) and the closest tertiary amine (desosamine 3′-N, N-dimethyl, 
which corresponds to the mycaminose 3′-N, N-dimethyl in 11) to the histidine 19 side chain 
within the active-site H19-D110 acid–base pair.
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Key HMBC and COSY correlations for compounds 1a and 2a.
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Additional tertiary-amine-containing OleD substrates trichostatin A (9), ZM 336372 (10), 
and tilmicosin (11) and their products. Tertiary amines within 9–11 are shaded yellow, and 
key HMBC and COSY correlations are highlighted.
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